Sun, Jun 23, 2019 - Page 5 News List

New drug to boost women’s sex drive approved in US, but questions linger

AP, WASHINGTON

US women would soon have another drug option designed to boost low sex drive: A shot they can give themselves in the thigh or abdomen that raises sexual interest for several hours.

The medication approved on Friday by the US Food and Drug Administration (FDA) is only the second approved to increase sexual desire in women, a market drugmakers have been trying to cultivate since the blockbuster success of Viagra for men in the late 1990s.

The other drug is a daily pill.

The upside of the new drug “is that you only use it when you need it,” said Julia Johnson, a reproductive specialist at UMass Memorial Medical Center who was not involved in its development. “The downside is that it’s a shot — and some people are very squeamish.”

The drug’s developer, Amag Pharmaceuticals, could also face some of the same hurdles that have plagued the lone pill previously approved for the condition, including unpleasant side effects and limited insurance coverage.

The company declined to release price information.

The FDA approved the new drug, Vyleesi, for premenopausal women with a disorder defined by a persistent lack of interest in sex, causing stress. The most common side effect in company studies was nausea.

“Women are not desiring more sex. They want better sex,” Amag chief medical officer Julie Krop said.

The condition, known as hypoactive sexual desire disorder, is not universally accepted and some psychologists argue that low sex drive should not be considered a medical problem.

Still, the pharmaceutical industry has long pointed to surveys — some funded by drugmakers — suggesting that it is the most common female sexual disorder in the US, affecting about one in 10 women.

Cynthia Pearson, executive director of the National Women’s Health Network, urged women to avoid using the drug “until more is known about its safety and effectiveness.”

She said in a statement that Amag had not yet published full clinical trial results.

The search for a pill to treat women’s sexual difficulties was once a top priority for many of the world’s biggest drugmakers, including Pfizer, Bayer and Procter & Gamble.

Those companies and others studied and later abandoned drugs acting on blood flow, testosterone and other targets.

Vyleesi acts on receptors for a brain-stimulating hormone called melanocortin, which is associated with sexual arousal and appetite in men and women.

This story has been viewed 1418 times.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top